<DOC>
	<DOCNO>NCT00334893</DOCNO>
	<brief_summary>This phase II trial study well eribulin mesylate work treat patient recurrent ovarian epithelial , primary peritoneal cavity , fallopian tube cancer . Drugs use chemotherapy , eribulin mesylate , work different way stop growth tumor cell , either kill cell stop dividing .</brief_summary>
	<brief_title>Eribulin Mesylate Treating Patients With Recurrent Ovarian Epithelial , Primary Peritoneal Cavity , Fallopian Tube Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine frequency objective response ( complete partial response ) patient recurrent ovarian epithelial , primary peritoneal cavity , fallopian tube cancer treat E7389 ( eribulin mesylate ) . SECONDARY OBJECTIVES : II . Determine toxicity profile drug patient . OUTLINE : This multicenter study . Patients stratify accord prior platinum sensitivity ( yes v ) . Patients receive eribulin mesylate intravenously ( IV ) 15 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm ovarian epithelial , primary peritoneal cavity , fallopian tube cancer Recurrent disease ≥ 1 prior therapy , meet 1 follow criterion : Platinumresistant disease ( progressionfree interval &lt; 6 month ) Platinumsensitive disease ( progressionfree interval ≥ 6 month ) Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mmby conventional technique OR ≥ 10 mm spiral CT scan No known brain metastasis Life expectancy &gt; 2 month ECOG performance status ( PS ) 01 OR Karnofsky PS 70100 % Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ WBC ≥ 3,000/mm^3 Bilirubin normal AST ALT ≤ 2.5 time upper limit normal Creatine normal OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior invasive malignancy within past 5 year except nonmelanoma skin cancer Stage IA IB endometrial cancer within past 5 year allow provide patient consider disease free No history allergic reaction attribute compound similar chemical biological composition E7389 No HIV positivity No ongoing active infection No cardiac arrhythmia No unstable angina pectoris No symptomatic congestive heart failure No psychiatric illness social situation would preclude study compliance No uncontrolled intercurrent illness See Disease Characteristics Recovered effect recent surgery , radiotherapy , chemotherapy No 2 prior cytotoxic therapy 1 non platinum , non taxane regimen No prior E7389 More 14 day since prior hormonal therapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) More 4 week since prior radiotherapy No concurrent antitumor hormonal therapy No concurrent investigational agent No concurrent anticancer agent therapies No granulocyte colonystimulating factor first course study therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>